Consolidated Net Income/Loss (Annual)

Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.

Catalyst Pharmaceuticals, Inc. (CPRX) had Consolidated Net Income/Loss of $163.89M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$491.73M
Net Income	$163.89M
Cost of Goods Sold	$68.84M
Gross Profit	$422.89M
Operating Expenses	$296.61M
Operating Income	$195.12M
Non-Operating Income/Expense	$21.14M
Pre-Tax Income	$216.26M
Normalized Pre-Tax Income	$216.26M
Income after Taxes	$163.89M
Income from Continuous Operations	$163.89M
Consolidated Net Income/Loss	$163.89M
Normalized Income after Taxes	$163.89M
EBIT	$195.12M
EBITDA	$232.90M
Weighted-Average Shares Outstanding (Basic)	118.46M
Weighted-Average Shares Outstanding (Diluted)	124.94M
Earnings per Share (EPS) (Basic)	$1.38
Earnings per Share (EPS) (Diluted)	$1.31
Balance Sheet Financials
Current Assets	$623.61M
Property, Plant, and Equipment	$1.35M
Long-Term Assets	$227.80M
Total Assets	$851.41M
Current Liabilities	$120.68M
Long-Term Debt	--
Long-Term Liabilities	$3.10M
Total Liabilities	$123.78M
Common Equity	$727.63M
Tangible Shareholders Equity	$570.96M
Shareholders Equity	$727.63M
Common Shares Outstanding	120.88M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$239.81M
Cash Flow from Investing Activities	$-0.56M
Cash Flow from Financial Activities	$140.66M
Beginning Cash	$137.64M
End Cash	$517.55M
Increase/Decrease in Cash	$379.92M
Stock-Based Compensation	$22.25M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.17
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	--
Debt to Equity Ratio	--
Gross Margin	86.00%
Operating Margin	39.68%
EBIT Margin	39.68%
EBITDA Margin	47.36%
Pre-Tax Profit Margin	43.98%
Profit Margin	33.33%
Free Cash Flow	$239.25M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.58
Inventory Turnover	3.52
Receiveable Turnover	7.51
Days Sales in Receivables	48.60
Return on Equity	22.52%
Return on Tangible Equity	28.70%
Return on Assets	19.25%
Return on Investments	22.52%
Book Value Per Share	$6.02
Free Cash Flow per Share	$1.91
Operating Cash Flow per Share	$1.92

Data from Zacks Investment Research, Inc.